Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews


Researchers at the University of Pennsylvania have developed a microfluidic chip that mimics the placental barrier. Their device paves the way for drug screening to determine which drugs can cross the placental barrier, allowing researchers to assess drug safety for pregnant women. Pharmacological treatment for pregnant women can be risky, as some drugs can cross the placental barrier and could potentially affect the fetus. Researchers don’t yet fully understand how the placenta permits some molecules to pass through it, and blocks the passage of others.

Read more ...

Orthotaxy’s Technology Will Be Leveraged to Develop Cost-Effective, Time-Efficient, User-Friendly Offering in a Broad Range of Orthopaedics Procedures. Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery technologies, including a differentiated robotic-assisted surgery solution.

Read more ...

CE-IVD labeled PAXgene® Blood ccfDNA tube will be available in Western Europe. BD (Becton, Dickinson and Company) a global medical technology company, announced the commercial availability of the CE-IVD marked PAXgene® Blood ccfDNA tube within the European Economic Area and Switzerland (Western Europe).

Read more ...

PoN market growth is driven mainly by PoC applications (human diagnostics), which enable the rapid analysis of patients’ samples out of reference laboratories, in a decentralized way. Therefore, PoC diagnostics allow patients to receive an appropriate treatment faster, and reduce costs by lowering the duration and frequency of a hospital stay. Some tests are also used to monitor a patient’s condition over time.

Read more ...

Synergia Medical SA, an opto-electronics pioneer developing next generation medical devices for neurostimulation, announces that it has raised €8.1 million in a Series A funding round from new and existing investors. New investor Newton Biocapital led the Series A round and was joined by other new investors Financière Spin-off Luxembourgeoise and Belgian regional growth funds SRIW (Société Régionale d'Investissement de Wallonie) and SFPI-FPIM (Belgian Federal Holding and Investment Company). The funds will be used to bring Synergia’s vagus nerve stimulation device NAOS through final testing prior to CE mark submission.

Read more ...

GenePOC member of the Debiopharm Group™, is proud to announce the launch in its home market for the revogene instrument and the GenePOC™ GBS LB assay.

About Group B Streptococcus (GBS) in Canada

GBS is the leading cause of infection in infants worldwide with a fatality rate between 4-6%. The SOGC guideline recommends universal antepartum screening for women at 35-37 weeks of gestation, along with intrapartumantibiotic prophylaxis. While this has resulted in a decrease in early onset disease (EOD) rate, there is still an ongoing need for more sensitive GBS detection.

Read more ...

Upcoming Events

> Medisens
(February 26 - February 27, London, UK)

> CRISPR & precision genome editing
(February 28 - February 28, Boston, USA)

> Medical Wearables 2018
(May 16 - May 17, Santa Clara, California)


No events


BioMEMS, the next big thing for MEMS players ?
Discover the presentation held by Sébastien Clerc at MEMS & Sensors Executive Congress, in ...
Status of the Microfluidics Industry
Discover the presentation held by Sébastien Clerc at Sensor China Conference of September 1...
Status of the Microfluidics Industry
Discover the presentation held by Benjamin Roussel at EAC Annual Conference 2017, in Singap...

Access to all our presentations